Advertisements

Eto (Etofenamate)

Quick links to important sections

Eto (Etofenamate)

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Eto (Etofenamate)

Property Description
Active Ingredient Etofenamate
Primary Form Topical Gel, Cream, or Spray
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Relief of localized pain and swelling
Origin Synthetic small molecule

What Type of Medicine is Etofenamate?

Etofenamate is a synthetic active pharmaceutical ingredient classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging to the Fenamate chemical subgroup. This compound is designated with the ATC code M02AA06 for anti-inflammatory topical preparations. As an NSAID, the substance is used to relieve localized pain and discomfort by managing inflammatory responses. Chemically, Etofenamate is a glycol ester of flufenamic acid, a structure that functions as a pro-drug, which is converted into the therapeutically active metabolite after absorption into the tissue. This specific chemical structure supports its efficacy profile when compared to simpler topical NSAID formulations.


Composition and Available Forms of Etofenamate

Etofenamate is formulated as a single-active-ingredient product, most commonly designed for topical/transdermal application, which is utilized for achieving targeted site delivery. The preparations typically include pharmaceutical forms such as topical gels, creams, lotions, or sprays, primarily utilizing hydroalcoholic or cream bases to facilitate the penetration of the drug through the skin. The use of these topical forms allows for concentrated action on localized areas of discomfort. Less common forms, available in certain regions, include suppositories and solutions intended for intramuscular injection, offering alternative administration options for specific therapeutic needs.


General Purpose: Relief of Pain and Inflammation

The general therapeutic purpose of Etofenamate is to reduce inflammation and provide analgesia (pain relief) directly at the site of muscle or joint discomfort. Its mechanism of action involves the principle of inhibiting the synthesis of prostaglandins, which are the chemical messengers that initiate and sustain the sensation of pain and the process of swelling. This targeted biological intervention supports the management of acute or chronic localized inflammatory conditions by mitigating the localized inflammatory cascade.

Advertisements

What side effects are possible with Eto (Etofenamate)?

Possible Side Effects and Safety Information

The official safety profile of Etofenamate, a Nonsteroidal Anti-inflammatory Drug (NSAID) primarily used topically, details adverse reactions based on frequency and affected physiological systems. The majority of documented effects are localized to the site of application.


Frequency and System-Organ Classes

The most commonly listed adverse reactions are categorized as Skin and Subcutaneous Tissue Disorders. These effects include pruritus (itching), erythema (redness), local irritation, and a burning feeling. Less common reactions can involve a more generalized rash or contact dermatitis. Rare documented events include blistering and urticaria (hives).

Classification Example Reactions (Local)
Common Pruritus, Erythema, Local irritation, Burning feeling
Rare Contact dermatitis
Very Rare Urticaria, Blistering

Serious adverse reactions are categorized as very rare but include systemic responses such as anaphylactic reactions and severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS). Regulatory data notes that the risk of systemic side effects, such as those affecting the gastrointestinal or renal systems typical of oral NSAIDs, is significantly lower but is not entirely excluded with use over large areas or for prolonged periods.


Population-Specific Safety Considerations

Specific safety constraints are documented for certain populations. The medicine is generally contraindicated in individuals with severe renal impairment and severe hepatic impairment. Furthermore, its use is generally restricted or contraindicated during the third trimester of pregnancy and is not recommended during breastfeeding, reflecting a general safety pattern for the NSAID class.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Etofenamate topical gel indicates that no cases of overdose have been reported with the product. Due to the low systemic absorption rate from the skin, the likelihood of poisoning following normal topical use is considered low. However, official prescribing information details the necessary response for situations involving accidental or excessive exposure.

The principal regulatory concern is the accidental oral ingestion of the gel, which can lead to systemic absorption of the active ingredient. In this scenario, the official guidance mandates that individuals seek immediate medical attention. This action is required whenever an overdose or accidental ingestion is known or suspected. Potential clinical manifestations following significant systemic exposure are generally extrapolated from the Nonsteroidal Anti-inflammatory Drug (NSAID) class and may include symptoms such as headaches, dizziness, or gastrointestinal discomfort.

Management of a potential systemic overdose focuses on symptomatic and supportive treatment, as no specific antidote is known or documented for Etofenamate. For instances involving the application of excessive amounts of the gel to the skin, official guidance specifies that the excess product should be removed promptly, typically by washing the affected area with water. There are no specific population-based overdose considerations explicitly detailed in the product-specific regulatory information.

Advertisements

Therapeutic Uses of Eto (Etofenamate)

What Etofenamate Treats: Main Uses and Benefits

Etofenamate (Eto) is generally used to help manage symptoms related to localized conditions. These include addressing symptoms of localized inflammatory or irritative states, such as those related to muscle and joint discomfort. This medication is applied across domains where short-term symptomatic assistance is needed to help patients cope with disruptive symptoms. This application supports various symptom axes within these therapeutic domains.


Key Areas of Symptom Relief

Etofenamate is relevant in contexts marked by increased discomfort or tension, such as when symptoms involve physical discomfort. It helps address symptom clusters that may become intense or disruptive, including those associated with acute or disruptive episodes. It is commonly used for managing symptoms related to physical discomfort and functional stress. Eto contributes to improved comfort during periods of heightened symptoms.

“This medicine is applied across domains where additional symptomatic support is needed, particularly for conditions characterized by periods of heightened symptoms.”

This medicine is helpful in situations requiring additional symptomatic assistance when symptoms interfere with routine activities. Etofenamate contributes to easing the overall symptom load, which may assist with maintaining functional stability when symptoms create noticeable physiological strain.


Quick Fact: Support for Symptomatic Discomfort

Quick Fact: Support for Symptomatic Discomfort

Etofenamate is commonly used when symptoms intensify and supportive relief is needed during phases of increased distress or discomfort.

Regulatory References

  1. HPRA Summary of Product Characteristics for Etoflam Gel
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Status

Etofenamate is officially allowed for use in Adults (including the elderly). Its eligibility is primarily defined by a series of absolute prohibitions and population restrictions stated in regulatory documents, reflecting its classification as a Non-Steroidal Anti-inflammatory Drug (NSAID).

Category Regulatory Status Rule Basis
Hypersensitivity Contraindicated Allergy to Etofenamate or any other NSAID, including aspirin.
Skin Integrity Contraindicated Must not be applied to damaged skin, open wounds, areas of eczema, or ulcers.
Pediatric Use Not Recommended Use in children and infants (typically under 14 years) is not recommended due to lack of established safety data.
Pregnancy/Lactation Not Recommended Use during both pregnancy and breastfeeding is not recommended.
Organ Function Conditional Use Patients with impaired renal function require caution, especially when the medicine is applied extensively or for prolonged periods, to minimize systemic exposure risk.

Summary of Restrictions

Absolute contraindications prohibit use for individuals with a history of NSAID-related allergies and mandate avoidance of application to any compromised skin surface or simultaneously with other topical preparations. Regulatory documents classify the use of Etofenamate in pediatric populations and during pregnancy/lactation as not recommended.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for topical etofenamate emphasizes that the potential for systemic drug interactions is unlikely when the product is used in accordance with the authorized dose, due to low systemic exposure. However, the official profile documents several interactions, primarily concerning additive pharmacodynamic effects that could occur if significant systemic absorption is achieved.

Documented Pharmacodynamic Interactions

Interacting Substance Category Official Interaction Statement
Anticoagulants (e.g., Enoxaparin) Co-administration may increase the haemorrhagic effect (risk of bleeding).
Diuretics May decrease the effectiveness of diuretics.
ACE Inhibitors / AIIA May decrease the effectiveness of the antihypertensive medicine. Co-administration may also result in the progression of renal function deterioration, including acute renal insufficiency.

Administration-Related Restriction

Regulatory documentation mandates a specific restriction for co-administration: The use of this product simultaneously to the same site with any other topical preparation is contraindicated. There are no explicitly documented interactions with food, alcohol, or herbal products for the topical formulation.

Population-Specific Notes

The potential interaction with ACE Inhibitors and AIIA resulting in renal function concerns should be particularly considered for elderly patients and individuals with impaired renal function, as stated in the official prescribing information.

Advertisements

Mechanism of Action

Etofenamate functions as a prodrug that undergoes conversion into the active molecule, flufenamic acid, directly within the affected tissue. This compound acts as a reversible competitive inhibitor of the two key enzymes in the eicosanoid cascade: Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2). This targeted molecular action forms the basis of the drug's mechanistic profile.

Molecular Inhibition of the Prostaglandin Synthesis Pathway

This mechanism involves the primary biological targets, COX-1 and COX-2, whose inhibition reduces the conversion of arachidonic acid into pro-inflammatory mediators, chiefly prostaglandins. This suppression of the eicosanoid pathway reduces the production of these chemical messengers, which are involved in propagating the physiological response following tissue damage.

Modulation of Local Nociceptive and Vascular Signaling

The resulting reduction in local prostaglandin concentration directly affects peripheral physiology by decreasing the sensitization of peripheral sensory neurons and modulating the local vascular permeability. This dual action on both nerve signaling and blood vessel function leads to predictable physiological adjustments in nociceptor sensitivity and edema formation within the affected tissue compartment.

Advertisements

Dosage and Administration Information

Administration Guidelines

Etofenamate is administered via the cutaneous (topical) route and the intramuscular (IM) route, with each pathway following distinct procedural instructions.

The primary method of use is topical application with a gel, cream, or spray. For the 5% w/w gel, the adult dose involves gently rubbing a strip of gel, typically 5–10 cm in length, onto the affected area. This application may be repeated up to four times daily. After application, hands should be thoroughly washed, unless the hands are the site of treatment.

Treatment duration involves specific review periods. For localized soft tissue conditions, therapy is typically reviewed after 14 days, and the total duration of use should not extend beyond six weeks. For the symptomatic management of osteoarthritis, the period for therapy review is typically four weeks.

An alternative route is the Intramuscular (IM) Injection, which is generally reserved for circumstances where topical application is considered unsuitable. The standard dose is a single ampoule, administered by deep injection into the muscle tissue.

Regarding specific populations, the topical use of etofenamate is not recommended in children or infants due to a lack of clinical experience. No change to the recommended topical dose is needed for older adults or patients with known renal or hepatic impairment. In the event an application is occasionally forgotten, the scheduled applications should continue as usual.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etofenamate (Eto)


Evidence for Localized Musculoskeletal Pain and Acute Injuries

Research has explored etofenamate in studies involving conditions where symptoms may vary in intensity, such as localized pain from acute or disruptive episodes like sprains, strains, or contusions, as well as low back discomfort (lumbago). The majority of the evidence in this area comes from short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies primarily involved adult patients and measured outcomes related to physical discomfort, specifically assessing changes in pain intensity and localized swelling over a defined time interval.

Studies were conducted during periods of increased symptom activity, and research highlights changes measured during the study period in groups using etofenamate compared to groups using an inactive vehicle (placebo) or groups receiving other commercially available topical NSAIDs. Research describes patterns observed in the studies related to these outcomes linked to inflammatory or irritative states. What remains uncertain is the need for more up-to-date and comparative evidence that directly measures etofenamate against all newer topical formulations currently available.


Evidence in Studies Exploring Symptomatic Patterns in Localized Osteoarthritis

Etofenamate research explored conditions characterized by functional limitations, such as localized osteoarthritis (OA) of the knee. The research base includes RCTs that compared etofenamate against placebo or other treatments, with a focus on outcomes reflecting daily functioning or activity level. The study populations focused on adult patients with symptomatic mild to moderate OA. In these trials, research examined changes in patient-reported outcomes describing perceived discomfort over defined time intervals, with follow-up durations often running for four to twelve weeks.

Research focusing specifically on etofenamate for OA often has limited long-term data (beyond three months) from dedicated controlled trials, meaning the observation of long-lasting symptom patterns is not fully established. Furthermore, the evidence quality varies across studies due to the different formulations and varied trial designs. Data for certain groups, such as very older adults with multiple health conditions or those with severe OA, remain insufficient, and the subgroup findings are uncertain.


Evidence Gaps and Areas of Uncertainty

Due to the short-term focus of most research, the follow-up durations were limited across key studies, meaning there is limited information for long-term outcomes or durability of findings. Overall, the research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Summary of Product Characteristics (Etoflam Gel, Etofenamate) - Health Products Regulatory Authority (HPRA)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Eto (Etofenamate) (FAQ)


Q: Is Etofenamate considered a steroid medicine?

Etofenamate is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This chemical designation confirms that it is not a steroid medicine, but it belongs to the Fenamate subgroup of anti-inflammatory compounds, according to official international classifications.


Q: What specific kinds of soft tissue injuries is Etofenamate used for?

Official product information indicates that Etofenamate is authorized for the treatment of localized inflammatory disorders of the musculoskeletal system. This includes common conditions such as sprains, strains, contusions, and specific forms of low back discomfort.


Q: Is Etofenamate thought to cause fewer gastrointestinal side effects than taking pain pills?

Regulatory data notes that the risk of systemic side effects, such as those affecting the gastrointestinal system typical of oral NSAIDs, is considered significantly lower with topical use. This finding is attributed to the drug’s low systemic exposure (the limited amount that enters the bloodstream).


Q: Can Etofenamate be used by people who are taking blood thinners like warfarin?

The official interaction statement describes that co-administration with anticoagulants (medicines that reduce blood clotting) may be associated with an increased risk of bleeding (haemorrhagic effect). This class of medicine includes warfarin.


Q: Is it safe to use Etofenamate if a person is already taking an oral NSAID?

Official information emphasizes the low systemic risk of the topical form. However, regulatory information describes that due to the potential for combined exposure to multiple NSAIDs, there may be a risk of additive side effects from the cumulative systemic exposure.


Q: Are there any known issues with using Etofenamate while taking blood pressure medicine?

Official documents specify potential interactions with certain types of blood pressure medication, specifically ACE Inhibitors and AIIA. These interactions may decrease the effectiveness of the blood pressure medicine and carry a documented risk of renal (kidney) function deterioration.


Q: Can Etofenamate interact with other creams or lotions applied to the same area?

Regulatory documentation strictly states that it is contraindicated to use Etofenamate simultaneously to the same site with any other topical preparation, which includes other creams or lotions.


Q: What conditions related to the stomach or intestines are listed as a caution for Etofenamate use?

Etofenamate is officially contraindicated in individuals who have a peptic ulcer. This reflects a safety constraint related to the NSAID class, although the systemic risk is lower for the topical form.


Q: Is the absorption of Etofenamate affected by applying tight bandages over the area?

Yes. Official product instructions advise that the product should not be used with tight bandages or occlusive dressings. This guidance is included to ensure the product is used in accordance with the official administration instructions.


Q: Is Etofenamate the same type of ingredient found in all over-the-counter pain gels?

No. Etofenamate is a synthetic NSAID belonging to the Fenamate chemical subgroup. While many topical gels contain NSAIDs, Etofenamate's specific chemical structure distinguishes it from other common ingredients like diclofenac or ibuprofen.


Q: Can Etofenamate be used for general body pain that is not injury-related?

Official indications for the product focus on the localized relief of pain and inflammation in muscles and soft tissues related to specific injuries or conditions like localized osteoarthritis. Regulatory documents do not support its use for non-localized, general body pain.


Q: Is there research comparing Etofenamate to other topical pain relief products?

Yes. Research overviews included in official documentation indicate that studies have measured Etofenamate against both an inactive vehicle (placebo) and groups receiving other commercially available topical NSAIDs.


Q: Does Etofenamate build up in the body or at the application site with repeated use?

Pharmacokinetic studies track the body's processing of the drug. These studies describe measurable systemic exposure, meaning detectable plasma levels of the drug or its active metabolite are found in serum and joint fluid during long-term use.


Q: What should be done immediately if Etofenamate accidentally gets into the eyes or mouth?

Official safety instructions state that contact with the eyes or mucous membranes must be avoided. If accidental eye contact occurs, instructions advise to wash the eyes immediately and contact a doctor. If swallowed, contact a doctor or Poison Control Center immediately.


Q: Is it necessary to massage the gel into the skin for it to work correctly?

Official administration instructions advise to rub the gel in gently onto the affected area. The instructions specify gentle rubbing as the technique but do not strictly mandate vigorous massaging for the drug to work.


Q: Why is alcohol sometimes included in Etofenamate gel formulations?

Alcohol is often included in the hydroalcoholic gel base as an inactive ingredient. Its purpose is to act as a solvent for the drug and to facilitate the efficient penetration of the drug through the skin barrier to reach the deeper affected tissue.


Q: Is there research showing Etofenamate works better than a non-medicated plaster or cream?

Yes. Research overviews indicate that clinical trials compared Etofenamate directly against an inactive vehicle (placebo). This comparison is used to assess if the active drug works better than a non-medicated form of the preparation.


Q: Does Etofenamate contain ingredients that help it penetrate the skin barrier?

Yes. Official information notes that Etofenamate is readily transported through the skin. The formulations are designed with specialized bases, such as a hydroalcoholic base, to facilitate efficient drug penetration and absorption into the tissue.


Q: Can Etofenamate make skin more sensitive to sun exposure or UV light?

Yes, official safety information indicates this is a known risk. NSAIDs, the class of medicine Etofenamate belongs to, have been reported in safety literature to induce photosensitivity reactions (increased sensitivity to sunlight or UV light).


Q: Is it possible for Etofenamate to cause side effects such as headache or dizziness?

While the most common adverse reactions are localized to the application site, official safety data sheets list general systemic symptoms like headache and dizziness as potential, though less common, adverse reactions.


Q: Is Etofenamate considered appropriate for use in older adults?

Official dosing guidelines state that the recommended topical dosage for Adults (including the elderly) is the same as for other adults. The label also notes that studies have not indicated a need to change the recommended dose for older patients.


Q: Does Etofenamate primarily act on the surface of the skin or penetrate deeper into the tissue?

According to official pharmacodynamics data, Etofenamate is readily transported through the skin and is converted into the active anti-inflammatory molecule directly within the affected tissue. It is intended to penetrate beyond the skin surface to the underlying inflamed area.


Q: Do different Etofenamate forms (gel, cream, plaster) work differently on the body?

The active anti-inflammatory effect is provided by the same molecule regardless of the form. The differences lie in the delivery method, with the various forms (gel, cream, plaster) designed to optimize the efficient delivery of the drug through the skin barrier.

Advertisements

How should Eto (Etofenamate) be stored and disposed of?

How to Store and Dispose of Etofenamate

Official regulatory guidelines define specific conditions for storing and disposing of Etofenamate to maintain its quality and ensure safety.

Storage Requirements

Condition Regulatory Rule
Temperature Store at or below 25 C.
Prohibitions Do not refrigerate or freeze the product.
Packaging Keep in the original container and ensure it is kept tightly closed.
Stability Use the topical gel within six months after first opening the tube.
Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Etofenamate must not be disposed of via wastewater or regular household waste due to environmental restrictions. To discard the medicine, individuals must consult a pharmacist for guidance on proper pharmaceutical take-back or disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eto (Etofenamate) found in:

A-Z Index: